FLEX Study

Agendia is a leading molecular diagnostics company focused on providing genomic insights to improve treatment outcomes for breast cancer patients. The company's core products, MammaPrint and BluePrint, utilize gene expression profiling to assess the risk of recurrence and identify tumor molecular subtypes, enabling personalized therapeutic strategies. Agendia's FLEX Study is a large-scale, prospective, observational registry that captures whole-genome expression data and clinical outcomes, serving as a powerful real-world evidence platform for oncology research. By integrating genomic data with clinical practice, Agendia aims to optimize decision-making and support the development of targeted therapies in the breast cancer space.